Fatty acid binding protein 5 (FABP5) has been reported to play an important role in various cancers. We found that high FABP5 expression was associated with poor histological differentiation and vascular invasion. High FABP5 expression indicated a poor prognosis. Downregulation of FABP5 suppressed cell proliferation, cell migration and invasion, and induced cell apoptosis. Bioinformatic analysis revealed that the Hippo signaling pathway was related to FABP5. We found that overexpression of yes-associated protein 1 (YAP1) could partially reverse the effect of FABP5 knockdown on growth and apoptosis. The FABP5 inhibitor SBFI-26 suppressed the proliferation and promoted the apoptosis of gastric cancer (GC) cells and interfered with the Hippo signaling pathway by inhibiting YAP1. Our data suggested that FABP5 might act as a potential target associated with the Hippo signaling pathway for GC treatment.
Get full access to this article
View all access options for this article.
References
1.
AjaniJ.A., D'AmicoT.A., AlmhannaK., BentremD.J., ChaoJ., DasP., et al. (2016). Gastric cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 14, 1286–1312.
2.
Al-JameelW., GouX., ForootanS.S., Al FayiM.S., RudlandP.S., ForootanF.S., et al. (2017). Inhibitor SBFI26 suppresses the malignant progression of castration-resistant PC3-M cells by competitively binding to oncogenic FABP5. Oncotarget, 8, 31041–31056.
3.
ApayaM.K., HsiaoP.-W., YangY.-C., and ShyurL.-F. (2020). Deregulating the CYP2C19/Epoxy-eicosatrienoic acid-associated FABP4/FABP5 signaling network as a therapeutic approach for metastatic triple-negative breast cancer. Cancers 12,199.
4.
BarbusS., TewsB., KarraD., HahnM., RadlwimmerB., DelhommeN., et al. (2011). Differential retinoic acid signaling in tumors of long- and short-term glioblastoma survivors. J Natl Cancer Inst, 103, 598–606.
5.
BergerW.T., RalphB.P., KaczochaM., SunJ., BaliusT.E., RizzoR.C., et al. (2012). Targeting fatty acid binding protein (FABP) anandamide transporters—a novel strategy for development of anti-inflammatory and anti-nociceptive drugs. PLoS One 7,e50968.
6.
BrayF., FerlayJ., SoerjomataramI., SiegelR.L., TorreL.A., and JemalA. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 68, 394–424.
7.
CamardaR., ZhouA.Y., KohnzR.A., BalakrishnanS., MahieuC., AndertonB., et al. (2016). Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer. Nat Med, 22, 427–432.
8.
CanuV., DonzelliS., SacconiA., Lo SardoF., PulitoC., BosselN., et al. (2020). Aberrant transcriptional and post-transcriptional regulation of SPAG5, a YAP-TAZ-TEAD downstream effector, fuels breast cancer cell proliferation. Cell Death Differ [Epub ahead of print]; DOI: 10.1038/s41418-020-00677-9.
9.
CarbonettiG., ConversoC., ClementT., WangC., TrotmanL.C., OjimaI., et al. (2020). Docetaxel/cabazitaxel and fatty acid binding protein 5 inhibitors produce synergistic inhibition of prostate cancer growth. Prostate, 80, 88–98.
10.
CurrieE., SchulzeA., ZechnerR., WaltherT.C., and FareseR.V.Jr. (2013). Cellular fatty acid metabolism and cancer. Cell Metab, 18, 153–161.
11.
DongJ., FeldmannG., HuangJ., WuS., ZhangN., ComerfordS.A., et al. (2007). Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell, 130, 1120–1133.
12.
DongS.R., JuX.L., and YangW.Z. (2019). STAT5A reprograms fatty acid metabolism and promotes tumorigenesis of gastric cancer cells. Eur Rev Med Pharmacol Sci, 23, 8360–8370.
13.
EgeN., DowbajA.M., JiangM., HowellM., HooperS., FosterC., et al. (2018). Quantitative analysis reveals that actin and Src-family kinases regulate nuclear YAP1 and its export. Cell Syst, 6, 692–708.e13.
14.
Elosegui-ArtolaA., AndreuI., BeedleA.E.M., LezamizA., UrozM., KosmalskaA.J., et al. (2017). Force triggers YAP nuclear entry by regulating transport across nuclear pores. Cell, 171, 1397–1410.e14.
15.
FangL.Y., WongT.Y., ChiangW.F., and ChenY.L. (2010). Fatty-acid-binding protein 5 promotes cell proliferation and invasion in oral squamous cell carcinoma. J Oral Pathol Med, 39, 342–348.
16.
FuruhashiM., and HotamisligilG.S. (2008). Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov, 7, 489–503.
17.
GruberR., PanayiotouR., NyeE., Spencer-DeneB., StampG., and BehrensA. (2016). YAP1 and TAZ control pancreatic cancer initiation in mice by direct up-regulation of JAK-STAT3 signaling. Gastroenterology, 151, 526–539.
18.
HotamisligilG.S., and BernlohrD.A. (2015). Metabolic functions of FABPs—mechanisms and therapeutic implications. Nat Rev Endocrinol, 11, 592–605.
19.
HsiaoY.H., ChenN.C., KohY.C., NagabhushanamK., HoC.T., and PanMH. (2019). Pterostilbene inhibits adipocyte conditioned-medium-induced colorectal cancer cell migration through targeting FABP5-related signaling pathway. J Agr Food Chem, 67, 10321–10329.
20.
HuangJ., WuS., BarreraJ., MatthewsK., and PanD. (2005). The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila Homolog of YAP. Cell, 122, 421–434.
21.
JeonS.M., ChandelN.S., and HayN. (2012). AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature, 485, 661–665.
22.
Kannan-ThulasiramanP., SeachristD.D., MahabeleshwarG.H., JainM.K., and NoyN. (2010). Fatty acid-binding protein 5 and PPARbeta/delta are critical mediators of epidermal growth factor receptor-induced carcinoma cell growth. J Biol Chem, 285, 19106–19115.
23.
KonsavageW.M.Jr., KylerS.L., RennollS.A., JinG., and YochumG.S. (2012). Wnt/beta-catenin signaling regulates Yes-associated protein (YAP) gene expression in colorectal carcinoma cells. J Biol Chem, 287, 11730–11739.
24.
KoshiyamaA., IchibangaseT., and ImaiK. (2013). Comprehensive fluorogenic derivatization-liquid chromatography/tandem mass spectrometry proteomic analysis of colorectal cancer cell to identify biomarker candidate. Biomed Chromatogr, 27, 440–450.
25.
LeviL., LoboG., DoudM.K., von LintigJ., SeachristD., TochtropG.P., et al. (2013). Genetic ablation of the fatty acid-binding protein FABP5 suppresses HER2-induced mammary tumorigenesis. Cancer Res, 73, 4770–4780.
26.
LeviL., WangZ., DoudM.K., HazenS.L., and NoyN. (2015). Saturated fatty acids regulate retinoic acid signalling and suppress tumorigenesis by targeting fatty acid-binding protein 5. Nat Commun 6,8794.
27.
LuJ., HuangC.M., ZhengC.H., LiP., XieJ.W., WangJ.B., et al. (2013). Consideration of tumor size improves the accuracy of TNM predictions in patients with gastric cancer after curative gastrectomy. Surg Oncol, 22, 167–171.
28.
LvQ., WangG., ZhangY., HanX., LiH., LeW., et al. (2019). FABP5 regulates the proliferation of clear cell renal cell carcinoma cells via the PI3K/AKT signaling pathway. Int J Oncol, 54, 1221–1232.
29.
MorganE., Kannan-ThulasiramanP., and NoyN. (2010). Involvement of fatty acid binding protein 5 and PPARbeta/delta in prostate cancer cell growth. PPAR Res 2010,234629.
30.
NishioM., SugimachiK., GotoH., WangJ., MorikawaT., MiyachiY., et al. (2016). Dysregulated YAP1/TAZ and TGF-beta signaling mediate hepatocarcinogenesis in Mob1a/1b-deficient mice. Proc Natl Acad Sci U S A, 113, E71–E80.
31.
OhataT., YokooH., KamiyamaT., FukaiM., AiyamaT., HatanakaY., et al. (2017). Fatty acid-binding protein 5 function in hepatocellular carcinoma through induction of epithelial-mesenchymal transition. Cancer Med, 6, 1049–1061.
32.
OudhoffM.J., FreemanS.A., CouzensA.L., AntignanoF., KuznetsovaE., MinP.H., et al. (2013). Control of the hippo pathway by Set7-dependent methylation of Yap. Dev Cell, 26, 188–194.
33.
PanJ., DaiQ., ZhangT., and LiC. (2019). Palmitate acid promotes gastric cancer metastasis via FABP5/SP1/UCA1 pathway. Cancer Cell Int 19,69.
34.
SeoJ., JeongD.W., ParkJ.W., LeeK.W., FukudaJ., and ChunY.S. (2020). Fatty-acid-induced FABP5/HIF-1 reprograms lipid metabolism and enhances the proliferation of liver cancer cells. Commun Biol 3,638.
35.
ThanosP.K., ClavinB.H., HamiltonJ., O'RourkeJ.R., MaherT., KoumasC., et al. (2016). Examination of the addictive and behavioral properties of fatty acid-binding protein inhibitor SBFI26. Front Psychiatry 7,54.
36.
ThulasiramanP., McAndrewsD.J., and MohiudddinI.Q. (2014). Curcumin restores sensitivity to retinoic acid in triple negative breast cancer cells. BMC Cancer 14,724.
37.
VigneswaranK., BoydN.H., OhS.Y., LallaniS., BoucherA., NeillS.G., et al. (2020). YAP/TAZ transcriptional co-activators create therapeutic vulnerability to verteporfin in EGFR mutant glioblastoma. Clin Cancer Res, 27, 1553–1569.
38.
WangW., ChuH.J., LiangY.C., HuangJ.M., ShangC.L., TanH., et al. (2016). FABP5 correlates with poor prognosis and promotes tumor cell growth and metastasis in cervical cancer. Tumour Biol, 37, 14873–14883.
39.
WuG., XuY., WangQ., LiJ., LiL., HanC., et al. (2019). FABP5 is correlated with poor prognosis and promotes tumour cell growth and metastasis in clear cell renal cell carcinoma. Eur J Pharmacol 862,172637.
40.
XiaoY., ZhangH., MaQ., HuangR., LuJ., LiangX., et al. (2019). YAP1-mediated pancreatic stellate cell activation inhibits pancreatic cancer cell proliferation. Cancer Lett, 462, 51–60.
41.
ZhangC., LiaoY., LiuP., DuQ., LiangY., OoiS., et al. (2020). FABP5 promotes lymph node metastasis in cervical cancer by reprogramming fatty acid metabolism. Theranostics, 10, 6561–6580.
42.
ZhangZ., DuJ., WangS., ShaoL., JinK., LiF., et al. (2019). OTUB2 promotes cancer metastasis via Hippo-independent activation of YAP and TAZ. Mol Cell, 73, 7–21.e7.
43.
ZhuP., WangY., DuY., HeL., HuangG., ZhangG., et al. (2015). C8orf4 negatively regulates self-renewal of liver cancer stem cells via suppression of NOTCH2 signalling. Nat Commun 6,7122.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
